P - Contraindicated in pregnancy
L - Contraindicated in lactation
Information Not Available
Glimepiride stimulates the insulin release from functioning pancreatic β-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
Information Not Available
Diarrhoea, vomiting, metallic taste, rash, isolated transaminase elevations, cholestatic jaundice, allergic skin reactions, photosensitivity reactions, leukopaenia, agranulocytosis, thrombocytopaenia, haemolytic anaemia, aplastic anaemia, pancytopaenia, blurred vision.
Potentially Fatal: Lactic acidosis.
Information Not Available
Renal and hepatic impairment. Avoid alcohol consumption. Hypoglycaemic episodes.
Concomitant admin with propranolol increases Cmax, AUC, and T1/2 of glimepiride. Aspirin increases the mean AUC of glimepiride. Furosemide increases the Cmax of metformin.
Potentially Fatal: NSAIDS, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid, MAOs, and beta blockers potentiate the hypoglycemic action of glimepiride.
Information Not Available
Oral
Type 2 diabetes mellitus
Adult: Per tablet contains glimepiride 1 mg and metformin 250 mg or glimepiride 2 mg and metformin 500 mg: Take as directed. Titrate according to response.
Information Not Available
Contraindicated in pregnancy
Contraindicated in lactation
Information Not Available
Information Not Available
Hypersensitivity diabetic ketoacidosis (DKA); renal dysfunction; CHF (CHF), patients undergoing radiological studies; acute or chronic metabolic acidosis. Pregnancy, lactation.
Information Not Available
Information Not Available
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.